Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C1140680 (
ovarian cancer
)
28,141
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
N6-methyladenosine (m
6
A) RNA methylation, involved in cancer initiation and progression, is dynamically regulated by the m
6
A RNA methylation regulators. However, the expression of m
6
A RNA methylation regulators in
ovarian cancer
and their correlation with prognosis remain elusive. Here, we demonstrated that the 18 central m
6
A RNA methylation regulators were expressed differently between
ovarian cancer
(OC) and normal tissues. By applying consensus clustering, all
ovarian cancer
patient cases can be divided into three subgroups (cluster1/2/3) based on overall expression levels of all 18 m
6
A RNA methylation regulators. We systematically analyzed the prognostic value of transcription levels of 18 m
6
A RNA methylation regulators in
ovarian cancer
and found that insulin-like growth factor 2 mRNA binding protein 1 (IGF2BP1), vir like m
6
A methyltransferase associated (VIRMA), and
zinc finger CCCH-type containing 13
(ZC3H13) yield the highest scores for predicting the prognosis of
ovarian cancer
. Accordingly, we derived a risk signature consisting of transcription levels of these three selected m
6
A RNA methylation regulators as an independent prognostic marker for OC and validated our findings with data derived from a different
ovarian cancer
cohort. Moreover, by the Gene Set Enrichment Analysis (GSEA), we demonstrated that the three selected regulators were all correlated with pathways in cancer and WNT signaling pathways. In conclusion, m
6
A RNA methylation regulators are vital participants in
ovarian cancer
pathology; and IGF2BP1, VIRMA, and ZC3H13 mRNA levels are valuable factors for prognosis prediction and treatment strategy development.
...
PMID:A newly defined risk signature, consisting of three m
6
A RNA methylation regulators, predicts the prognosis of ovarian cancer. 3295 Sep 70
